DDX5 and hepatocellular carcinoma: In liver cancer cell lines and preclinical HCC models sorafenib and mTKIs downregulate DDX5 (Figs. 2 and 3), and DDX5KD cell lines exhibit reduced sensitivity to sorafenib [24].